Last reviewed · How we verify

Urinary frequency — Treatment Landscape & Competitive Intelligence

Urinary frequency (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Urinary frequency, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Nuceiva BOTULINUM TOXIN TYPE A GlaxoSmithKline K.K. Acetylcholine Release Inhibitor [EPC] Synaptosomal-associated protein 25 2019-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. GlaxoSmithKline K.K. · 1 drug in Urinary frequency

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Urinary frequency:

Cite this brief

Drug Landscape (2026). Urinary frequency — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/urinary-frequency. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing